Related references
Note: Only part of the references are listed.Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair
Fumi Higuchi et al.
CLINICAL CANCER RESEARCH (2020)
PARP inhibitors in ovarian cancer
Elisena Franzese et al.
CANCER TREATMENT REVIEWS (2019)
Preventive Effect of Naringin on Metabolic Syndrome and Its Mechanism of Action: A Systematic Review
Sivanesan Raja Kumar et al.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2019)
The Effect of Green and Black Tea Polyphenols on BRCA2 Deficient Chinese Hamster Cells by Synthetic Lethality through PARP Inhibition
Shaherah Alqahtani et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors
Ekta Rathi et al.
JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION (2019)
PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity
Shiv K. Gupta et al.
FRONTIERS IN ONCOLOGY (2019)
The Therapeutic Potential of Naringenin: A Review of Clinical Trials
Bahare Salehi et al.
PHARMACEUTICALS (2019)
Molecular Dynamics Simulations of the Interactions between Glial Cell Line-Derived Neurotrophic Factor Family Receptor GFRα1 and Small-Molecule Ligands
Larisa Ivanova et al.
ACS OMEGA (2018)
PARP Inhibition by Flavonoids Induced Selective Cell Killing to BRCA2-Deficient Cells
Cathy Su et al.
PHARMACEUTICALS (2017)
Synthesis and evaluation of selected 1,3,4-oxadiazole derivatives for in vitro cytotoxicity and in vivo anti-tumor activity
Amit Tiwari et al.
CYTOTECHNOLOGY (2016)
Binding-affinity predictions of HSP90 in the D3R Grand Challenge 2015 with docking, MM/GBSA, QM/MM, and free-energy simulations
Majda Misini Ignjatovic et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2016)
Temozolomide resistance in glioblastoma multiforme
Sang Y. Lee
GENES & DISEASES (2016)
Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide
Khaled Messaoudi et al.
DRUG DISCOVERY TODAY (2015)
Glioblastoma: From Molecular Pathology to Targeted Treatment
Timothy F. Cloughesy et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 9 (2014)
Docking Challenge: Protein Sampling and Molecular Docking Performance
Khaled M. Elokely et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2013)
Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
C. Leonetti et al.
CURRENT CANCER DRUG TARGETS (2012)
Molecular mechanisms of temozolomide resistance in glioblastoma multiforme
Tor-Christian Aase Johannessen et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Temozolomide: Mechanisms of Action, Repair and Resistance
Jihong Zhang et al.
Current Molecular Pharmacology (2011)
Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase
Kirk E. Hevener et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2009)
Expression and activity, of poly(ADP-ribose) glycohydrolase in cultured astrocytes, neurons, and C6 glioma cells
MB Sevigny et al.
MOLECULAR BRAIN RESEARCH (2003)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
